Kendall Capital Partners
- Company typePrivate
- Founded2021
- HeadquartersBoston, United States
- Headcount1–10
- GTM typeB2B
- OfferingServices
Kendall Capital Partners firmographics
Firmographics- Name
- Kendall Capital Partners
- Legal name
- Kendall Capital Partners
- Website
- https://kcpventures.com
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Ownership category
- akta.pro rank
Kendall Capital Partners industry classification
Industry- Product category
- Venture Capital / Life Sciences Investment
- NAICS
- Portfolio Management and Investment Advice (52394), Investment Banking and Securities Intermediation (523150)
- SIC
- Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)
- akta.pro primary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
- akta.pro secondary industries
- Early-Stage Venture Capital (Series A/B) (FSANAAAB), Corporate Finance & Capital Advisory (BPAHADAB)
Keywords
Where Kendall Capital Partners is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Kendall Capital Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Distribution channels3 records
Marketing channels3 records
Kendall Capital Partners product offering
Product offeringCore offering
Kendall Capital Partners is a Boston-based venture capital firm that invests in early-to-commercial stage life sciences and healthcare companies. The firm deploys capital from institutional LPs, family offices, and HNWIs into biotech startups developing gene and cell therapies, next-generation immunotherapies, advanced drug delivery systems, and AI/computational biology platforms. Beyond capital, the firm provides scientific guidance, operational support, board-level governance, and exit planning to portfolio companies.
Product overview
Kendall Capital Partners is a venture capital firm that does not develop or sell its own products or services. It operates as an investment platform that provides capital, strategic guidance, and operational support to early-to-commercial stage life sciences and healthcare companies. The firm's portfolio companies include Eyenuk (AI eye screening), General Fluidics (point-of-care blood diagnostics), Centivax (universal vaccine technology), Bilayer Therapeutics (metabolic disorder treatments), Rejuvenate Bio (gene therapy for aging), and EpiBone (regenerative bone and cartilage technology).
Differentiator
Problem solved
Functional benefit
Products and services
- Venture Capital Investment Fund Venture capital fund deploying LP capital into early-to-commercial stage life sciences and healthcare companies developing breakthrough medical technologies across gene/cell therapies, immunotherapies, drug delivery, and AI/computational biology. Provides portfolio companies with capital, scientific guidance, board-level governance, and operational support.
- Portfolio Company Strategic Support Strategic and operational support services provided to portfolio companies throughout the company-building journey, including go-to-market strategy, board-level governance, pivotal hiring support, strategic pivot guidance, and pre-exit planning. Targeted at founders and management teams of portfolio biotech and healthcare companies.
Companies that use Kendall Capital Partners
Customer profileSegments2 records
Ideal customer profiles2 records
Kendall Capital Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Kendall Capital Partners partnerships and signals
Strategic signalPartnerships
Two partnerships are on record, tiered core.
- Merck Animal HealthcoreMerck Animal Health entered into a strategic R&D collaboration with Rejuvenate Bio to develop gene therapy programs targeting age-related diseases in companion animals. This is one of the world's largest animal health companies, signaling mainstream industry engagement with longevity biotechnology.
- Phibro Animal HealthcoreRejuvenate Bio previously entered an agreement with Phibro Animal Health, validating the company's gene therapy technology and strategy for animal health applications prior to the Merck partnership.
Scale indicators2 records
Recent moves5 records
Expansion highlights6 records
Kendall Capital Partners competitors and assessment
Company assessmentDirect peers
- Flagship Pioneering: Cambridge-based biotech venture creation firm that originates and builds platform companies. Like Kendall, Flagship concentrates on breakthrough life sciences and has a deeply scientific partner bench (e.g., Noubar Afeyan), making it the most direct comparable in the sector-focused biotech VC category.
- Atlas Venture: Boston-based early-stage life sciences VC that builds biotech companies from inception through clinical proof-of-concept. Overlaps directly with Kendall on early-stage therapeutics, gene/cell therapy, and platform biotech investing in the Boston/Cambridge ecosystem.
- ARCH Venture Partners: Long-tenured biotech-focused VC investing across company formation, early, and growth stages. Comparable to Kendall as a sector-focused specialist backing transformative life sciences companies from frontier science through commercial milestones.
- OrbiMed: Healthcare-dedicated investment firm covering venture, growth, and public equity across therapeutics, medical devices, and diagnostics. Directly comparable as a healthcare-only specialist with a global LP base similar to Kendall's institutional and family office investors.
- RA Capital Management: Boston-based healthcare-focused investment manager operating a crossover fund and dedicated biotech venture strategy. Comparable to Kendall on Boston biotech focus, life sciences sector specialization, and crossover/private investing model.
- 5AM Ventures: Boston and San Francisco-based early-stage life sciences VC that builds companies around frontier science. Directly comparable as an early-stage sector specialist investing in therapeutics and platform technologies.
- Section 32: Venture fund founded by former Google Ventures head Bill Maris that invests broadly in technology and life sciences. Comparable as a sector-spanning investor with substantial biotech allocation and a founder-friendly approach to early-stage healthcare.
Broad incumbents
- Lux Capital: Tech-and-science focused VC that has built out life sciences and biotech investing alongside its broader AI and frontier-tech portfolio. Comparable as an investor in breakthrough science and AI/computational biology, though broader than Kendall's pure healthcare focus.
- Andreessen Horowitz (Bio + Health): Major venture firm with a dedicated Bio + Health practice investing across therapeutics, digital health, and biotech infrastructure. Comparable as a high-profile investor in frontier healthcare and AI-enabled biology, though operating as part of a much larger multi-sector platform.
- Alexandria Venture Investments: Strategic venture arm of Alexandria Real Estate Equities focused on life sciences companies across therapeutics, diagnostics, and research tools. Comparable as a life sciences sector specialist with deep relationships across biotech, though structured as a corporate CVC rather than an independent GP.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
Kendall Capital Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kendall Capital Partners leadership team
Management profileNumber of profiles
Profiles6 records
Kendall Capital Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kendall Capital Partners M&A and investment
M&A and investmentM&A
Investments10 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kendall Capital Partners
What does Kendall Capital Partners do?
Kendall Capital Partners is a Boston-based venture capital firm that invests in early-to-commercial stage life sciences and healthcare companies. The firm deploys capital from institutional LPs, family offices, and HNWIs into biotech startups developing gene and cell therapies, next-generation immunotherapies, advanced drug delivery systems, and AI/computational biology platforms. Beyond capital, the firm provides scientific guidance, operational support, board-level governance, and exit planning to portfolio companies.
Is Kendall Capital Partners a public or private company?
Kendall Capital Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Kendall Capital Partners founded?
Kendall Capital Partners was founded in 2021. It employs 1 to 10 people.
Where is Kendall Capital Partners based?
Kendall Capital Partners is headquartered in Boston, United States, in the North America region.
Who are Kendall Capital Partners's main competitors?
Direct peers on record are Flagship Pioneering, Atlas Venture, ARCH Venture Partners, OrbiMed, RA Capital Management, 5AM Ventures and Section 32. Broad incumbents are Lux Capital, Andreessen Horowitz (Bio + Health) and Alexandria Venture Investments.
Does Kendall Capital Partners have an API?
No public API is recorded for Kendall Capital Partners.
What industry is Kendall Capital Partners in?
Kendall Capital Partners's product category is Venture Capital / Life Sciences Investment. Its primary akta.pro industry code is FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists), with a secondary code of FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 52394 and its SIC code is 6282.